Home » Blog » Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4Rα, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)
Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4Rα, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)
6 Views
SaveSavedRemoved 0
Efficacy and security of rademikibart (CBP-201), a next-generation monoclonal antibody concentrating on IL-4Rα, in adults with moderate-to-severe atopic dermatitis: a section 2 randomized trial (CBP-201-WW001)
Trending Merchandise
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$25.00
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$29.71
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$32.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$13.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$17.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$7.85
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$8.83
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$45.40
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$9.99
Added to wishlistRemoved from wishlist 0
Carlyle Cat’s Claw Capsules 1000mg | 180 Count | Uncaria Tomentosa | Non-GMO, Gluten Free Supplement
Added to wishlistRemoved from wishlist 0
$15.28